Search Results - "Vij, R"

Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease by Choi, Jaebok, Cooper, Matthew L., Staser, Karl, Ashami, Kidist, Vij, Kiran R., Wang, Bing, Marsala, Lynne, Niswonger, Jessica, Ritchey, Julie, Alahmari, Bader, Achilefu, Samuel, Tsunoda, Ikuo, Schroeder, Mark A., DiPersio, John F.

“…The therapeutic benefits of allogeneic hematopoietic stem cell transplantation (allo-HSCT) are derived from the graft-versus-leukemia (GvL) effects of the…”
Get full text

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies by Siegel, David, Martin, Thomas, Nooka, Ajay, Harvey, R Donald, Vij, Ravi, Niesvizky, Ruben, Badros, Ashraf Z, Jagannath, Sundar, McCulloch, Leanne, Rajangam, Kanya, Lonial, Sagar

“…Carfilzomib, a selective proteasome inhibitor, was approved in 2012 for the treatment of relapsed and refractory multiple myeloma. Safety data for single-agent…”
Get full text

Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time by Kumar, S K, Dispenzieri, A, Fraser, R, Mingwei, F, Akpek, G, Cornell, R, Kharfan-Dabaja, M, Freytes, C, Hashmi, S, Hildebrandt, G, Holmberg, L, Kyle, R, Lazarus, H, Lee, C, Mikhael, J, Nishihori, T, Tay, J, Usmani, S, Vesole, D, Vij, R, Wirk, B, Krishnan, A, Gasparetto, C, Mark, T, Nieto, Y, Hari, P, D'Souza, A

“…Duration of initial disease response remains a strong prognostic factor in multiple myeloma (MM) particularly for upfront autologous hematopoietic cell…”
Get full text

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety by Badros, A Z, Vij, R, Martin, T, Zonder, J A, Kunkel, L, Wang, Z, Lee, S, Wong, A F, Niesvizky, R

“…This phase 2 study assessed the safety, pharmacokinetics, pharmacodynamics and efficacy of carfilzomib, a selective proteasome inhibitor, in patients with…”
Get full text

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects by Hurchla, M A, Garcia-Gomez, A, Hornick, M C, Ocio, E M, Li, A, Blanco, J F, Collins, L, Kirk, C J, Piwnica-Worms, D, Vij, R, Tomasson, M H, Pandiella, A, San Miguel, J F, Garayoa, M, Weilbaecher, K N

“…Proteasome inhibitors (PIs), namely bortezomib, have become a cornerstone therapy for multiple myeloma (MM), potently reducing tumor burden and inhibiting…”
Get full text

Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML by Rashidi, A, Slade, M, DiPersio, J F, Westervelt, P, Vij, R, Romee, R

“…Post-transplant cyclophosphamide (PT-Cy) is the backbone of GvHD prophylaxis following haploidentical hematopoietic cell transplantation (haplo-HCT). PT-Cy has…”
Get full text

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study by Jakubowiak, A J, Siegel, D S, Martin, T, Wang, M, Vij, R, Lonial, S, Trudel, S, Kukreti, V, Bahlis, N, Alsina, M, Chanan-Khan, A, Buadi, F, Reu, F J, Somlo, G, Zonder, J, Song, K, Stewart, A K, Stadtmauer, E, Harrison, B L, Wong, A F, Orlowski, R Z, Jagannath, S

“…Several cytogenetic abnormalities are associated with poor outcomes in multiple myeloma (MM). We prospectively analyzed the impact of cytogenetic abnormalities…”
Get full text

Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma by Sanfilippo, K. M., Gage, B., Luo, S., Weilbaecher, K., Tomasson, M., Vij, R., Colditz, G., Carson, K.

“…Abstract Zoledronic acid and pamidronate are the two bisphosphonates approved in the United States to reduce multiple myeloma skeletal complications. Little…”
Get full text

High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma by Wildes, T M, Finney, J D, Fiala, M, Gao, F, Vij, R, Stockerl-Goldstein, K, Carson, K R, Mikhael, J, Colditz, G

“…Randomized trials showing that high-dose therapy with autologous stem cell transplant (ASCT) improved the overall survival (OS) in multiple myeloma (MM)…”
Get full text

Do adults aged 70 years or older with acute myeloid leukemia benefit from allogeneic hematopoietic cell transplantation? by Rashidi, A, DiPersio, J F, Westervelt, P, Vij, R, Abboud, C N, Romee, R

Get full text

A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML by Ramsingh, G, Westervelt, P, Cashen, A F, Uy, G L, Stockerl-Goldstein, K, Abboud, C N, Bernabe, N, Monahan, R, DiPersio, J F, Vij, R

Get full text

Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation by Huselton, E, Slade, M, DiPersio, J F, Westervelt, P, Vij, R, Uy, G L, Fehniger, T A, Abboud, C N, Gao, F, Schroeder, M A, Romee, R

Get full text

PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB‐CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA by Vij, R., Schade, H., Trudel, S., Chang, A. C., Huang, J., Samineni, D., Sumiyoshi, T., Tsai, J., Wong, T., Harrison, S. J.

Get full text

B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE‐CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA‐3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL by Rodríguez‐Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A.K., Manier, S., Callander, N., Costa, L.J., Vij, R., Bahlis, N.J., Moreau, P., Solomon, S.R., Delforge, M., Berdeja, J., Truppel‐Hartmann, A., Yang, Z., Favre‐Kontula, L., Wu, F., Piasecki, J., Cook, M., Giralt, S.

Get full text

P963: EVOLUTION OF TREATMENT PATTERNS AND OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING A SECOND LINE OF THERAPY BETWEEN 2012 AND 2020: ANALYSIS OF THE PREAMBLE COHORT by Kuter, D., Goldschmidt, H., Cella, D., Petrucci, M. T., Moreau, P., Durie, B., Juarez‐Garcia, A., Trong, L., Gu, J., Hernandez Rivera, G., Dhanasiri, S., Marshall, T., Wang, J., Lacoin, L., Ramasamy, K., Vij, R.

Get full text

Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes by Bhamidipati, P K, DiPersio, J F, Stokerl-Goldstein, K, Rashidi, A, Gao, F, Uy, G L, Westervelt, P, Vij, R, Schroeder, M A, Abboud, C N, Keller, J W, Fehniger, T A, Romee, R

Get full text

P958: REAL‐LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSES FROM THE LOCOMMOTION STUDY by Einsele, H., Moreau, P., De Stefano, V., Dytfeld, D., Angelucci, E., Benjamin, R., Goldschmidt, H., Donk, N. W., Besemer, B., Scheid, C., Vij, R., ’. Groen‐Damen, E. I., Semerjian, M., Strulev, V., Schecter, J. M., Roccia, T., Nesheiwat, T., Wapenaar, R., Weisel, K., Mateos, M.‐V.

Get full text

A Tumor Growth Inhibition Model Based on M‐Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single‐Agent Carfilzomib Use by Jonsson, F, Ou, Y, Claret, L, Siegel, D, Jagannath, S, Vij, R, Badros, A, Aggarwal, S, Bruno, R

“…Change in tumor size estimated using longitudinal tumor growth inhibition (TGI) modeling is an early predictive biomarker of clinical outcomes for multiple…”
Get full text

PHARMACIST ATTITUDES TOWARDS ADMINISTRATION OF DEPOT-MEDROXYPROGESTERONE ACETATE FOR CONTRACEPTION IN THE OUTPATIENT SETTING by Ellenberg, K, Vij, R

Get full text

Does It Matter If You're Black or White: Relationship Between Race/Ethnicity and Fecundability in Intrauterine Insemination Cycles by Storer, B, Peck, J, Hansen, K.R, Khan, S, Vij, R, Craig, L.B

Get full text